Swedish Drugmaker Meda Spurns Mylan Approach

07.04.2014 - Swedish generic drugmaker Meda has rejected a takeover approach by U.S. rival Mylan to create a combined company worth around $24 billion. Reports said Mylan was exploring a bid at...